ch.oddb.org
 
Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
Fachinformation zu Nif-Atenil®:Sandoz Pharmaceuticals AG
Vollst. FachinformationDDDDrucken 
Gal.Form/Ther.Gr.Zusammens.Eigensch.Pharm.kinetikInd./Anw.mögl.Dos./Anw.Anw.einschr.Unerw.Wirkungen
Interakt.Überdos.Sonstige H.Swissmedic-Nr.Stand d. Info. 
C07FB03 - Atenolol and NifedipineATC-DDD Version 2016. Source: WHO
C - Cardiovascular System

This group comprises substances used for the treatment of cardiovascular conditions.
Drugs used for the treatment of hypertension are classified in C02 - Antihypertensives, C03 - Diuretics, C07 - Beta blocking agents, C08 - Calcium channel blockers, and C09 - Agents acting on the renin-angiotensin system. For the classification of combination products of antihypertensives from different ATC groups, the following ranking should be used, from higher to lower precedence: C09, C07, C08, and C03.

C07 - Beta Blocking Agents
 
C07F - Beta Blocking Agents, Other Combinations

Beta blocking agents in combination with ACE inhibitors are classified in C09BX - ACE inhibitors, other combinations.
Beta blocking agents in combination with ARBs are classified in C09DX - Angiotensin II receptor blockers (ARBs), other combinations.
Beta blocking agents in combination with statins are classified in C10BX.

See comments to C02L concerning the principles for assignment of DDDs for combined preparations.

C07FB - Beta Blocking Agents and Calcium Channel Blockers
 
C07FB03 - Atenolol and Nifedipine
2025 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home